FDA OKs Sanguina’s at-home test for anemia
People with anemia can now monitor levels of their hemoglobin with a simple test taken in the comfort of their homes. AnemoCheck Home, made by GRA-backed startup Sanguina , this month became the first at-home hemoglobin test kit to receive clearance by the U.S. Food and Drug Administration. Available only by prescription, the test involves a simple finger prick followed by the mixing of a blood droplet with a solution in a small tube; results are available in just two minutes. Sanguina, launched out of Georgia Tech, has received investment from GRA’s venture development program as well as GRA Venture Fund. • See Sanguina’s news release >
Members are invited to join G2G’s Monthly GBG Reporting Service Webinar on September 18, 2025 . The first portion ( 12:00–12:30 PM ET ) is free and open to all, offering a high-level overview of current federal funding trends. The second half ( 12:30–1:00 PM ET ) is a premium consultation available only to Georgia Life Sciences members, offering direct access to G2G’s expert team—who have helped secure over $550 million in non-dilutive government funding since 2007. Register here: https://www.g2gconsulting.com/event/non-dilutive-funding-g2gs-monthly-gbg-reporting-service-webinar-14-3/2025-09-18/ Key opportunities this month include DARPA’s Expedited Research Innovation System for CBRN threat defense technologies, BARDA’s I-CREATE diagnostic funding and VANGUARD biomanufacturing tools development (each offering up to $200,000), NIAID tuberculosis and influenza research units (up to $1.5–$2.5 million annually), DoD’s $4 million Advanced Medical Monitor development through MTEC, and multiple SBIR opportunities for sensors and field-deployable diagnostics (up to $209,575 for Phase I awards). The September GBG report highlights 13 immunology and infectious disease opportunities, 10 cognitive and brain health programs, and several biotechnology and biomanufacturing initiatives across federal agencies including the Army, ARPA-H, BARDA, and NSF. Georgia Life Sciences members can access the complete 29-page report with detailed deadlines and eligibility requirements [insert link or portal instructions here]. GLS members can access the full 29-page report with deadlines and submission details by logging into your member portal.
Protecting U.S. Leadership in Agricultural Biotechnology
Celebrating the Next Generation of Scientific Breakthroughs in Georgia
